BiotechTube

SAGE-547

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Super-refractory Status Epilepticus

Conditions

Super-refractory Status Epilepticus

Trial Timeline

Mar 21, 2014 → May 3, 2015

NCT ID
NCT02052739

About SAGE-547

SAGE-547 is a phase 1/2 stage product being developed by Supernus Pharmaceuticals for Super-refractory Status Epilepticus. The current trial status is completed. This product is registered under clinical trial identifier NCT02052739. Target conditions include Super-refractory Status Epilepticus.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (3)

NCT IDPhaseStatus
NCT02433314Pre-clinicalCompleted
NCT02285504Phase 2Completed
NCT02052739Phase 1/2Completed

Competing Products

2 competing products in Super-refractory Status Epilepticus

See all competitors
ProductCompanyStageHype Score
SAGE-547Supernus PharmaceuticalsPre-clinical
18
SAGE-547 + PlaceboSupernus PharmaceuticalsPhase 3
72

Other Products from Supernus Pharmaceuticals

ZULRESSO®Approved
80
APOKYNApproved
80
SPN-812Approved
80
SPN-812Approved
80
100mg SPN-812 + PlaceboApproved
80